Accelerate Diagnostics, Tucson, Arizona, USA
Departments of Medicine and Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
J Clin Microbiol. 2018 Apr 25;56(5). doi: 10.1128/JCM.00139-18. Print 2018 May.
Antimicrobial resistance is the most pressing medical challenge of the past decade. At the front line are clinical laboratories, which are responsible for accurately reporting antimicrobial susceptibility test (AST) results to clinicians and public health authorities. The ability of the laboratory to detect resistance has been hampered by several factors. In 2016, the 21st Century Cures Act was signed into law, marking an important step toward resolving many regulatory dilemmas that hampered development and updates to commercial AST systems (cASTs). We describe the pathway and history of U.S. regulation of cASTs and outline both the rewards and unmet needs possible from the 21st Century Cures Act.
抗菌药物耐药性是过去十年中最紧迫的医学挑战。临床实验室处于这一挑战的最前线,负责向临床医生和公共卫生部门准确报告抗菌药物敏感性检测(AST)结果。实验室检测耐药性的能力受到多种因素的影响。2016 年,《21 世纪治愈法案》签署成为法律,这标志着解决许多监管难题迈出了重要一步,这些难题阻碍了商业 AST 系统(cASTs)的开发和更新。我们描述了美国对 cASTs 的监管途径和历史,并概述了《21 世纪治愈法案》可能带来的回报和未满足的需求。